Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05136053 · ClinicalTrials.gov registry record · Phase 1
A Study Investigating Lu AG22515 in Healthy Adults
A Phase 1 study of Healthy Participants, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
- 2
- Study locations
NCT05136053: Completed Phase 1 study of Healthy Participants, sponsored by H. Lundbeck A/S.
NCT05136053 is a Phase 1 study of Healthy Participants that has completed, run by H. Lundbeck A/S. The registered enrollment target is 58 participants, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (11% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05136053, a Phase 1 study of Healthy Participants, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main goal of this study is to learn more about the safety of a drug called Lu AG22515. During the trial, healthy adult participants will receive a single dose of Lu AG22515 or a placebo (normal saline solution).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lu AG22515
- DRUG Immune System Activator
Study Locations (2)
California
- CenExel CNS - Long Beach
New Jersey
- Frontage Clinical Research Inc - Secaucus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2022-03-18 |
| Est. Completion | 2023-08-05 |
| Phase | Phase 1 |
What the finished NCT05136053 record still lists
NCT05136053 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (11% lower).
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05136053 reports a single indexed study location in California, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05136053 about?
NCT05136053 is a clinical study titled "A Study Investigating Lu AG22515 in Healthy Adults". The main goal of this study is to learn more about the safety of a drug called Lu AG22515. During the trial, healthy adult participants will receive a single dose of Lu AG22515 or a placebo (normal saline solution).
What is the current status of trial NCT05136053?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2022-03-18. Estimated completion is 2023-08-05.
What conditions does trial NCT05136053 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT05136053?
The interventions under investigation include: Placebo (DRUG), Lu AG22515 (DRUG), Immune System Activator (DRUG).
Who is sponsoring clinical trial NCT05136053?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05136053 being conducted?
This trial has 2 study locations across California, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05136053's enrollment target sits among peer trials
58 43rd of 119 higher than 77 of 119 other Healthy Participants trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI